

## Hikma assigned investment grade status from Fitch Ratings

**London, October 22, 2020** – Fitch Ratings has today announced that it has assigned Hikma Pharmaceuticals Plc (Hikma, Company) a 'BBB-' first-time Long-Term Issuer Default Rating (outlook: Stable). Hikma's existing rating of BBB- (outlook: Stable) from S&P remains unchanged, and accordingly the Company has achieved investment grade status from two rating agencies.

Khalid Nabilsji, CFO of Hikma said: "I am pleased to announce that Hikma has achieved investment grade status with two ratings agencies. Fitch's announcement today confirms Hikma's solid market position as well as our track record of profitability and cash generation."

- ENDS -

### Enquiries

#### Hikma Pharmaceuticals PLC

Susan Ringdal  
EVP, Strategic Planning and Global Affairs

+44 (0)20 7399 2760/ +44 7776 477050  
[uk-investors@hikma.uk.com](mailto:uk-investors@hikma.uk.com)

### About Hikma

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P, BBB-/stable Fitch and Ba1/stable Moody's)

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: [www.hikma.com](http://www.hikma.com)

©2020 Hikma Pharmaceuticals PLC. All rights reserved.